The Blog
Improved Survival with Interferon Alpha Maintenance Therapy Following Pleurectomy-Decortication and Radiation for Malignant Pleural Mesothelioma
(As presented by Dr. Robert Cameron to the Society of Thoracic Surgeons, January 30, 2006. )
In this presentation, Dr. Cameron demonstrates that “maintenance therapy” such as interferon alpha may have a role in treating mesothelioma patients. The median survival of patients receiving interferon alpha after undergoing pleurectomy with decortication followed by surgery was 37 months.
View the publication abstract and the accompanying slides to see all of the research results by selecting any of the following:
Get a Free Copy
Testimonials
At age 12, Martha Munoz’s father uprooted the family from a comfortable life in Mexico to bring them to the United States. Her adopted country welcomed her hard work as a social worker, wife and mother. In 1996, as her husband Arturo was set to retire after 30 years of building cars at the local Ford Motor factory, Martha was also offered a retirement package from the county. Thus began a life of travel to Hawaii, Europe, Mexico and Texas while helping her children complete college and start their adult lives.Martha Munoz
Full Story
David Vanderhyde was diagnosed with pleural malignant mesothelioma (epithelial type – epithelium are tissue membranes that line the internal organs), in October 2006, and was instructed by his oncologist to begin chemotherapy right away. A month later, he began the standard regimen of Alimta with Cisplatin, however, his oncologist included a non-standard targeted therapy drug as well called Avastin (Bevacizumab), which is not a chemotherapy drug but rather an anti-angiogenesis therapy.David Vanderhyde
Full Story
Recent Tweets